Brought to you by 
J&J withdraws offer to acquire Guidant
10 Mar 2015
Executive Summary
Johnson & Johnson has agreed to acquire Guidant for approximately $25.38bn in cash and stock. Guidant shareholders will receive $30.40 in cash and $45.60 in J&J common stock, a 7% premium. The total consideration per Guidant share may be adjusted if J&J's trading price goes outside an agreed limit in the period before the deal closes.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com